文献速递糖尿病肥胖与代谢综合征

鞘氨醇作为GLP-1分泌的新型刺激因子

Sphinganine as a novel stimulator of GLP-1 secretion.
PubMed 文献 · Diabetologia · 2026-09-24

研究通过餐后血浆代谢组学发现鞘氨醇是GLP-1高反应的最强预测因子,并在体外细胞、人肠道类器官、大鼠肠道灌注及小鼠模型中验证其作用。鞘氨醇经GPR40机制使体外GLP-1分泌加倍,大鼠灌流中仅雄性显著增加,小鼠口服未急性升高GLP-1但长期喂养减少高脂饮食诱导的体重增加而不改变摄食。

要点

  • 鞘氨醇是餐后GLP-1高反应的最强血浆代谢预测因子。
  • 鞘氨醇经GPR40使体外GLP-1分泌加倍,大鼠灌流效应仅雄性显著。
  • 小鼠口服鞘氨醇不急性升GLP-1,但长期喂养减少高脂饮食增重。

核心结论

  • 鞘脂类具有有益代谢效应,鞘氨醇作为GLP-1分泌新型刺激因子值得探索治疗潜力。

研究设计与样本

  • 研究先对成人餐试血浆行代谢组学,再在GLUTag和NCI-H716细胞系及人肠道类器官体外、离体大鼠肠和结肠灌流及小鼠急性与长期喂养体内验证。

主要发现

  • 餐试血浆代谢组学中鞘氨醇是高GLP-1反应的最强预测因子。
  • 鞘氨醇经GPR40机制使体外多种细胞系和人肠道类器官GLP-1分泌加倍。
  • 离体大鼠肠道灌流中腔侧给鞘氨醇增加GLP-1,但仅雄性大鼠有统计学显著性。
  • 小鼠口服鞘氨醇急性或长期喂养后均未增加GLP-1。
  • 长期喂养模型中鞘氨醇减少高脂饮食诱导的体重增加,不改变摄食量。

局限性

  • 大鼠灌流中鞘氨醇增加GLP-1仅雄性有统计学显著性。
  • 小鼠口服鞘氨醇未在急性或长期喂养后增加GLP-1。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Mechanisms of secretion of the gut hormone glucagon-like peptide-1 (GLP-1) remain incompletely understood yet are relevant for the pathophysiology and treatment of obesity and diabetes. Here, we set out to identify novel triggers. METHODS: We started with using metabolomics on plasma samples from meal tests in adults, where we identified sphinganine, a sphingolipid, as the strongest predictor of a high GLP-1 response. Sphinganine was next tested in vitro (in GLUTag and NCI-H716 cell lines and human intestinal organoids), ex vivo (in isolated rat intestinal and colon perfusion models) and in vivo (using both single acute administration and prolonged feeding in mice). RESULTS: Sphinganine doubled GLP-1 secretion in vitro in multiple cell lines and human intestinal organoids, via G-protein-coupled receptor 40-mediated mechanisms. In isolated intestinal perfusion model in rats, sphinganine increased GLP-1 during luminal administration. However, this effect was only statistically significant in male rats. In vivo, oral administration of sphinganine to mice did not increase GLP-1 acutely or after prolonged feeding. In the prolonged-feeding model, however, it did reduce high-fat-diet-induced weight gain, without changing food intake. CONCLUSIONS/INTERPRETATION: Our data indicate beneficial metabolic effects of sphingolipids and points towards potential therapeutic effects to be explored.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Smits MM, Drzazga AK, Lackman JJ, et al. Sphinganine as a novel stimulator of GLP-1 secretion. Diabetologia. 2026. PMID: 42782508. doi:10.1007/s00125-026-06877-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。